On May 18, 2026, a Medtronic delegation led by Robert Kowal, Vice President and General Manager of Global Cardiac Rhythm Management, along with senior executives from Medtronic China, visited Meduco Medical, a subsidiary of Haofeng Group, for an in-depth tour and strategic discussion. The visit highlighted Meduco’s capabilities in interventional medical device CDMO services, including its advanced intelligent production lines, end-to-end quality control systems, and rapid delivery from concept to mass production. Medtronic commended Meduco’s technical expertise and operational excellence, reinforcing mutual trust and laying the groundwork for deeper collaboration in CDMO partnerships.

In April 2026, the global healthcare sector recorded 61 merger and acquisition transactions with a disclosed total value of approximately $36.17 billion. Of these, 8 deals occurred in China totaling $27.51 million, while 53 overseas transactions amounted to $36.145 billion. The digital health segment was the most active with 21 deals (34% of total), while medical devices and consumables led in deal value at $19.144 billion (52.92%). Notable transactions included TPG and Blackstone Group’s $18.3 billion acquisition of Hologic, Gilead Sciences’ $7.8 billion purchase of Arcellx, and BioMarin Pharmaceutical’s $4.8 billion acquisition of Amicus Therapeutics. Other significant deals involved Servier, GSK, Medtronic, and Chinese firms such as BGI Genomics, HaploX Biotechnology, and Ruisheng Bio.

A collaborative study by the University of Oxford and the University of California, San Francisco, based on 1,046 hours of chronic cortico-subthalamic nucleus (STN) recordings, reveals that dynamic neural states—not static beta-band oscillations—are the primary determinants of motor symptom severity in Parkinson’s disease (PD). The research involved five PD patients implanted with bilateral Medtronic Summit RC+S neural interfaces, using a four-state hidden Markov model (HMM) to decode continuous neural signals into distinct network states with unique spectral and temporal profiles. This approach overcomes limitations of traditional spectral averaging and resolves the paradox of variable spectral signatures underlying identical clinical symptoms, offering a new framework for precision neuromodulation therapies.

Edwards Lifesciences reported Q1 2026 revenue of $1.65 billion (approx. RMB 11.3 billion), up 16.7% year-over-year (12.7% constant currency), surpassing consensus estimates of $1.6 billion. Adjusted EPS came in at $0.78, above the expected $0.73. Two key developments drove the beat: accelerated TAVR growth following Boston Scientific’s exit from the European market—boosting Edwards’ global TAVR sales to $1.2 billion—and strong early commercial momentum in TMTT (Transcatheter Mitral and Tricuspid Therapies), with $173 million in revenue fueled by the recent FDA approval of Sapien M3, the first transseptal TMVR system. The company raised its full-year guidance for both total sales (now 9%–11% growth) and TAVR sales (7%–9% growth).

On April 21, 2026, Intuitive Surgical announced its first-quarter 2026 financial results, reporting $2.77 billion in revenue, a 23% year-over-year increase, and Non-GAAP EPS of $2.50, surpassing consensus estimates by $0.39. The company installed 431 da Vinci systems globally during the quarter, including 232 units of the next-generation da Vinci 5, which now accounts for 54% of new installations. Global procedure volume for da Vinci and Ion systems grew by approximately 17%, with da Vinci up 16% and Ion surging 39%. As of March 31, 2026, the global installed base reached 11,395 da Vinci systems and 1,041 Ion systems. Consumables and accessories remained the largest revenue segment at $1.686 billion (61% of total revenue), growing in line with procedure volume. The company faces an evolving competitive landscape with FDA approvals for rivals like Medtronic’s Hugo and CMR’s Versius, while maintaining strong margins and reaffirming its full-year procedure growth guidance of 13.5%–15.5%.

On April 9, 2026, Modular Medical (Nasdaq: MODD) announced that its tubeless patch insulin pump, Pivot, received FDA 510(k) clearance, with initial patient deliveries expected by the end of Q2 2026. Targeting 'almost-pumpers'—adults with type 1 or type 2 diabetes still using multiple daily injections (MDI)—Pivot features a two-part detachable design, a 3 mL replaceable reservoir, and a disposable battery. The pump enables bolus dosing via an onboard button and supports smartphone connectivity for monitoring and dosing. Positioned as a 'reusable + consumables' system to lower long-term costs, Pivot is the second FDA-cleared product from Modular Medical after MODD1. While lacking automated insulin delivery (AID) at launch, AID compatibility is in development. The company plans CE marking between Q4 2026 and Q1 2027 and currently has capacity for ~6,000 users.

Anteris Technologies has secured up to $90 million in strategic investment from Medtronic, granting Medtronic a 16.0%–19.99% equity stake, and is preparing a $200 million underwritten public offering. Proceeds will support the global pivotal PARADIGM trial of its novel, single-piece biomimetic TAVR—DurAVR—for severe aortic stenosis, as well as scale manufacturing capacity. DurAVR features ADAPT tissue technology, a decellularized, anti-calcification bovine pericardium platform clinically proven over 10 years. Early clinical data (n=100) show excellent hemodynamics (EOA: 2.2 ± 0.3 cm²; MPG: 8.2 ± 3.1 mmHg), zero valve-related deaths or moderate/severe paravalvular leak at 30 days, and only a 3.0% patient-prosthesis mismatch rate. With 100% technical success in the latest 50 consecutive implants, DurAVR represents a strategic addition to Medtronic’s structural heart portfolio amid intensifying competition with Edwards Lifesciences in the global TAVR market.

This prospectus analyzes the 2024–2025 competitive landscape of the global cardiovascular device market, valued at $72.83 billion, spotlighting the top five players—Medtronic, Abbott, Boston Scientific, Johnson & Johnson MedTech, and Edwards Lifesciences—who collectively command 58% of the market. Driven by high-growth segments like pulsed field ablation (PFA), transcatheter valve therapies (TAVR/TMTT), and leadless pacing, these giants leverage proprietary platforms such as Medtronic’s PulseSelect/Sphere-9, Abbott’s Volt PFA and Navitor TAVI, Boston Scientific’s FARAPULSE, J&J’s VARIPULSE, and Edwards’ SAPIEN series. The report details their revenue performance, technological differentiators, geographic strategies, and responses to challenges including U.S. pricing pressure, China’s volume-based procurement, and rising domestic competition. With PFA set to overtake radiofrequency ablation in 2025 and structural heart disease growing fastest, the race hinges on clinical evidence, procedural efficiency, and integrated care models.

Shenzhen CoreHeart Medical Technology Co., Ltd. has secured NMPA approval for China's first domestically developed percutaneous ventricular assist device (pVAD), comprising an介入式 left ventricular assist device and配套导管 pump kit. Utilizing proprietary miniaturized axial-flux multi-drive motor technology, the system delivers short-term left ventricular support during high-risk PCI procedures for adults with severe coronary artery disease and reduced ejection fraction. This breakthrough fills a critical domestic technological gap and challenges Abiomed’s global dominance in the pVAD market. CoreHeart Medical, already the market leader in China’s LVAD segment with over 45% share, is now advancing its STAR Market IPO amid strong growth projections for the global pVAD sector, expected to reach RMB 25 billion by 2031.

On November 24, 2025, the U.S. Centers for Medicare & Medicaid Services (CMS) finalized a rule effective January 1, 2026, adding atrial fibrillation (AF) catheter ablation to the Ambulatory Surgical Center (ASC) Covered Procedures List. This landmark decision establishes a reimbursement pathway for cardiac ablation in ASC settings for the first time, marking a pivotal shift toward outpatient electrophysiology. The policy aligns with clinical and industry efforts to advance Pulsed Field Ablation (PFA)—a faster, safer, and more ASC-compatible technology—into mainstream care. Leading PFA innovators Boston Scientific (Farapulse), Medtronic (Affera + PulseSelect), and Johnson & Johnson MedTech (Varipulse) are positioned as primary beneficiaries. The move reflects broader convergence of technological maturity, ASC capacity expansion, and payment reform, collectively enabling a structural scaling of AF treatment accessibility and market growth.